Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tocilizumab, Netakimab, and Baricitinib Versus Standard of Care Therapy in Patients With Mild to Moderate COVID-19 - a Retrospective Observational Study

NCT05302947 is registered in ClinicalTrials.gov with Pirogov Russian National Research Medical University as lead sponsor.

NCT NCT05302947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05302947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tocilizumab, Netakimab, and Baricitinib Versus Standard of Care Therapy in Patients With Mild to Moderate COVID-19 - a Retrospective Observational Study
Lead sponsor
Pirogov Russian National Research Medical University
Phase
Observational
Overall status
Completed
Start date
February 1, 2020
Completion date
June 30, 2021
Enrollment
154 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, mild to moderate